Skip to main content
Equibles
REPL logo

REPL · Replimune Group, Inc.

Track REPL — free

Use REPL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research REPL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$12.92 -0.32 (-2.42%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Going-concern doubt — cleared Aug 14, 2026

The latest filing states the doubt was alleviated.

“As described in the Company's Annual Report on Form 10-K for the year ended March 31, 2026, substantial doubt existed about the Company's ability to continue as a going concern. The conditions that raised substantial doubt have been subsequently alleviated, as the Company raised approximately $141.0 million in net proceeds from an equity offering in August 2026.”
View the 10-Q filed Aug 14, 2026
Market Cap
$1.22B
Shares
94.22M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$12.92 Open$13.33 Day$12.40–13.74 52W close$1.70–15.98 Avg vol 30d4.8M Short int23.5M · 25.0% float · 8.9d Short vol42% Last earningsAug 14, 2026 DataJan 2020–Sep 2026 Filing10-Q · Aug 14

Up next

Next earnings call
Feb 27, 2028 Est · unconfirmed · in 76 wks
Latest filing: 10-Q
filed Aug 14, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$297.01M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-22.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$111.21M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+5.8%
Year over year · more shares
Price change (1Y)
+121.0%
Trailing year
Short interest
25.0%
Latest settlement · 8.9 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +48%
above
Price vs 50-day avg +3%
above
RSI (14) 42
neutral
MACD trend Negative
52-week position 79%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −15%
trailing
6-month return +88%
trailing
YTD return +33%
this year
Relative strength +70%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $13 › 200d $9 — 50d above 200d
Institutional flow Accumulating
+9% holders QoQ · +73 funds added
Insider flow Distributing
Net -$1.0M over 90 days · 100% sells
Short interest Falling
24.96% of float · ▼ -5.4% MoM · 8.9 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
204 holders — near 3-yr high, broad support
Squeeze score 84
high risk · 0–100
Fundamentals
Weak
EPS growth −10%
Y/Y
Free cash flow $-282.6M
Balance sheet $117.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 217%
annualized · 1-yr
Max drawdown −84%
past year
ATR 7.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+48% Bullish
Price vs 50-day avg
+3% Bullish
RSI (14)
42 Neutral
MACD trend
Negative Bearish
52-week position
79% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $13 › 200d $9 — 50d above 200d
Institutional flow Accumulating
+9% holders QoQ · +73 funds added
Insider flow Distributing
Net -$1.0M over 90 days · 100% sells
Short interest Falling
24.96% of float · ▼ -5.4% MoM · 8.9 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
204 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2 Now $13 · 79% Range high $16
vs 200-day avg +48% vs 50-day avg +3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
REPL
Replimune Group, Inc.
this stock
$1.22B +32.9% — — 25.0%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.40B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.60B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
204
% held
110.4%
Net QoQ
+15.6M sh
Top holder
BAKER BROS. ADVISORS LP
Held Float
View
Held by Funds
Fund positions
150
View
Short & Settlement
Short Interest Falling
Shares short
23.5M
Days to cover
8.9d
Change
-1.3M sh
View
Short Volume
Short vol %
42%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
635.0K
Value
$9.7M
As of
Aug 13, 2026
View
Off-Exchange
Off-exchange %
41.0%
Week of
Aug 3, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$1.0M
Buyers / Sellers
0 / 4
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-313.9M
EPS diluted
$-3.38
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 14, 2026
This year
16
View
Proposed Sales
Value
$142.5K
Shares
18.5K
Filed
Apr 2, 2026
View
Earnings & Events
Earnings Calls
Last call
Aug 14, 2026
View

Performance

5D 20D 120D MTD YTD
REPL -15.5% -14.9% +87.5% -15.6% +32.9%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -14.4% -13.2% +69.7% -15.2% +20.8%
Key facts CIK 1737953 CUSIP 76029N106 13F (30d) 102 filings 102 filers Visit website Investor relations